NEW YORK, Oct. 27, 2008 (GLOBE NEWSWIRE) -- Promosome LLC, a biotechnology company specializing in innovative technologies related to the regulation of protein synthesis, today announced the successful completion of its Series B Funding Round. Initially seeking $7.5 million, Promosome has been successful in over-subscribing the round to a close of $9.6 million. These funds will be utilized to support the current commercialization efforts for its Translation Enhancing Elements (TEEs) technology as well as advancing other late stage development technologies.
